Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma
Elevated neutrophil to lymphocyte ratio (NLR) has been reported to be associated with worse survival in many malignancies, whereas its role in nasopharyngeal carcinoma (NPC) remains unclear. We retrospectively reviewed 363 consecutively, newly diagnosed, non-disseminated, and biopsy-proven NPC patie...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2011-04, Vol.32 (2), p.317-324 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 324 |
|---|---|
| container_issue | 2 |
| container_start_page | 317 |
| container_title | Tumor biology |
| container_volume | 32 |
| creator | An, Xin Ding, Pei-Rong Wang, Feng-Hua Jiang, Wen-Qi Li, Yu-Hong |
| description | Elevated neutrophil to lymphocyte ratio (NLR) has been reported to be associated with worse survival in many malignancies, whereas its role in nasopharyngeal carcinoma (NPC) remains unclear. We retrospectively reviewed 363 consecutively, newly diagnosed, non-disseminated, and biopsy-proven NPC patients. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to NLR level. Multivariate analysis was performed to assess the prognostic value of NLR. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR (> or ≤3.73) were 59.6% vs. 76.6% (
p
= 0.03), 69.7% vs. 86.6% (
p
= 0.002), and 78.5% vs. 87.3% (
p
= 0.105), respectively. For patients with locoregionally advanced disease, NLR was not only an independent prognostic factor, but also a predictor of response to chemoradiotherapy. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR were 47.2% vs. 73.7% (
p
|
| doi_str_mv | 10.1007/s13277-010-0124-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907181490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907181490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-b246d6ff57b76fa2532f7d495b76c4b86b2d2792770a91b3d9249774d4eff3ad3</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMo7rr6A7xI8OKpmqRpkxxlWT9A8KInDyFt0t0ubVOTVth_7yy7KgjiISTDPPNOZl6Ezim5poSIm0hTJkRCKIHDeCIO0JRyliYkleQQ3tsMZzKdoJMY14TQTKn8GE0YJRmTUk7R26JxH2ZwFnduHILvV3WDB4-bTduvfLkZHA5mqD3ug7N1OUTcex8g8svOxzriusOdiVBnwqZbOtPg0oSy7nxrTtFRZZrozvb3DL3eLV7mD8nT8_3j_PYpKXkuh6RgPLd5VWWiEHllWJaySliuMghLXsi8YJYJBZMSo2iRWsW4EoJb7qoqNTadoaudLvzqfXRx0G0dS9c0pnN-jFoRQSXlivxLSujNciIFkJe_yLUfQwdjAMQE40RJgOgOKoOPMbhK96FuYRGaEr11SO8c0uCD3jqkt8IXe-GxaJ39rviyBAC2AyKkYKPhp_Pfqp-yq5wA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>852724098</pqid></control><display><type>article</type><title>Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>An, Xin ; Ding, Pei-Rong ; Wang, Feng-Hua ; Jiang, Wen-Qi ; Li, Yu-Hong</creator><creatorcontrib>An, Xin ; Ding, Pei-Rong ; Wang, Feng-Hua ; Jiang, Wen-Qi ; Li, Yu-Hong</creatorcontrib><description>Elevated neutrophil to lymphocyte ratio (NLR) has been reported to be associated with worse survival in many malignancies, whereas its role in nasopharyngeal carcinoma (NPC) remains unclear. We retrospectively reviewed 363 consecutively, newly diagnosed, non-disseminated, and biopsy-proven NPC patients. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to NLR level. Multivariate analysis was performed to assess the prognostic value of NLR. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR (> or ≤3.73) were 59.6% vs. 76.6% (
p
= 0.03), 69.7% vs. 86.6% (
p
= 0.002), and 78.5% vs. 87.3% (
p
= 0.105), respectively. For patients with locoregionally advanced disease, NLR was not only an independent prognostic factor, but also a predictor of response to chemoradiotherapy. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR were 47.2% vs. 73.7% (
p
< 0.001), 59.2% vs. 85.1% (
p
< 0.001), and 72.3% vs. 84.6% (
p
= 0.041), respectively. Compared with radiation alone, chemoradiotherapy significantly improved DSS and LRFS for patients with non-elevated NLR, but not for those with elevated NLR. Pre-treatment NLR is a strong prognostic factor for NPC patients. For patients with locoregionally advanced disease, NLR might also be a useful indicator for selection of treatment strategies.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-010-0124-7</identifier><identifier>PMID: 21052888</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adolescent ; Adult ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Count ; Cellular biology ; Chemotherapy ; Child ; Combined Modality Therapy ; Drug Therapy ; Female ; Head & neck cancer ; Humans ; Longitudinal Studies ; Lymphocytes ; Lymphocytes - pathology ; Male ; Medical prognosis ; Middle Aged ; Nasopharyngeal Neoplasms - diagnosis ; Nasopharyngeal Neoplasms - pathology ; Nasopharyngeal Neoplasms - therapy ; Neutrophils - pathology ; Prognosis ; Radiation therapy ; Radiotherapy ; Research Article ; Retrospective Studies ; Secondary Prevention ; Survival Analysis ; Young Adult</subject><ispartof>Tumor biology, 2011-04, Vol.32 (2), p.317-324</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2010</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-b246d6ff57b76fa2532f7d495b76c4b86b2d2792770a91b3d9249774d4eff3ad3</citedby><cites>FETCH-LOGICAL-c468t-b246d6ff57b76fa2532f7d495b76c4b86b2d2792770a91b3d9249774d4eff3ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-010-0124-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-010-0124-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21052888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>An, Xin</creatorcontrib><creatorcontrib>Ding, Pei-Rong</creatorcontrib><creatorcontrib>Wang, Feng-Hua</creatorcontrib><creatorcontrib>Jiang, Wen-Qi</creatorcontrib><creatorcontrib>Li, Yu-Hong</creatorcontrib><title>Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>Elevated neutrophil to lymphocyte ratio (NLR) has been reported to be associated with worse survival in many malignancies, whereas its role in nasopharyngeal carcinoma (NPC) remains unclear. We retrospectively reviewed 363 consecutively, newly diagnosed, non-disseminated, and biopsy-proven NPC patients. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to NLR level. Multivariate analysis was performed to assess the prognostic value of NLR. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR (> or ≤3.73) were 59.6% vs. 76.6% (
p
= 0.03), 69.7% vs. 86.6% (
p
= 0.002), and 78.5% vs. 87.3% (
p
= 0.105), respectively. For patients with locoregionally advanced disease, NLR was not only an independent prognostic factor, but also a predictor of response to chemoradiotherapy. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR were 47.2% vs. 73.7% (
p
< 0.001), 59.2% vs. 85.1% (
p
< 0.001), and 72.3% vs. 84.6% (
p
= 0.041), respectively. Compared with radiation alone, chemoradiotherapy significantly improved DSS and LRFS for patients with non-elevated NLR, but not for those with elevated NLR. Pre-treatment NLR is a strong prognostic factor for NPC patients. For patients with locoregionally advanced disease, NLR might also be a useful indicator for selection of treatment strategies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Count</subject><subject>Cellular biology</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Combined Modality Therapy</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Nasopharyngeal Neoplasms - diagnosis</subject><subject>Nasopharyngeal Neoplasms - pathology</subject><subject>Nasopharyngeal Neoplasms - therapy</subject><subject>Neutrophils - pathology</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Research Article</subject><subject>Retrospective Studies</subject><subject>Secondary Prevention</subject><subject>Survival Analysis</subject><subject>Young Adult</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU1LxDAQhoMo7rr6A7xI8OKpmqRpkxxlWT9A8KInDyFt0t0ubVOTVth_7yy7KgjiISTDPPNOZl6Ezim5poSIm0hTJkRCKIHDeCIO0JRyliYkleQQ3tsMZzKdoJMY14TQTKn8GE0YJRmTUk7R26JxH2ZwFnduHILvV3WDB4-bTduvfLkZHA5mqD3ug7N1OUTcex8g8svOxzriusOdiVBnwqZbOtPg0oSy7nxrTtFRZZrozvb3DL3eLV7mD8nT8_3j_PYpKXkuh6RgPLd5VWWiEHllWJaySliuMghLXsi8YJYJBZMSo2iRWsW4EoJb7qoqNTadoaudLvzqfXRx0G0dS9c0pnN-jFoRQSXlivxLSujNciIFkJe_yLUfQwdjAMQE40RJgOgOKoOPMbhK96FuYRGaEr11SO8c0uCD3jqkt8IXe-GxaJ39rviyBAC2AyKkYKPhp_Pfqp-yq5wA</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>An, Xin</creator><creator>Ding, Pei-Rong</creator><creator>Wang, Feng-Hua</creator><creator>Jiang, Wen-Qi</creator><creator>Li, Yu-Hong</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma</title><author>An, Xin ; Ding, Pei-Rong ; Wang, Feng-Hua ; Jiang, Wen-Qi ; Li, Yu-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-b246d6ff57b76fa2532f7d495b76c4b86b2d2792770a91b3d9249774d4eff3ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Count</topic><topic>Cellular biology</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Combined Modality Therapy</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Nasopharyngeal Neoplasms - diagnosis</topic><topic>Nasopharyngeal Neoplasms - pathology</topic><topic>Nasopharyngeal Neoplasms - therapy</topic><topic>Neutrophils - pathology</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Research Article</topic><topic>Retrospective Studies</topic><topic>Secondary Prevention</topic><topic>Survival Analysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>An, Xin</creatorcontrib><creatorcontrib>Ding, Pei-Rong</creatorcontrib><creatorcontrib>Wang, Feng-Hua</creatorcontrib><creatorcontrib>Jiang, Wen-Qi</creatorcontrib><creatorcontrib>Li, Yu-Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>An, Xin</au><au>Ding, Pei-Rong</au><au>Wang, Feng-Hua</au><au>Jiang, Wen-Qi</au><au>Li, Yu-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>32</volume><issue>2</issue><spage>317</spage><epage>324</epage><pages>317-324</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Elevated neutrophil to lymphocyte ratio (NLR) has been reported to be associated with worse survival in many malignancies, whereas its role in nasopharyngeal carcinoma (NPC) remains unclear. We retrospectively reviewed 363 consecutively, newly diagnosed, non-disseminated, and biopsy-proven NPC patients. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to NLR level. Multivariate analysis was performed to assess the prognostic value of NLR. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR (> or ≤3.73) were 59.6% vs. 76.6% (
p
= 0.03), 69.7% vs. 86.6% (
p
= 0.002), and 78.5% vs. 87.3% (
p
= 0.105), respectively. For patients with locoregionally advanced disease, NLR was not only an independent prognostic factor, but also a predictor of response to chemoradiotherapy. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or non-elevated NLR were 47.2% vs. 73.7% (
p
< 0.001), 59.2% vs. 85.1% (
p
< 0.001), and 72.3% vs. 84.6% (
p
= 0.041), respectively. Compared with radiation alone, chemoradiotherapy significantly improved DSS and LRFS for patients with non-elevated NLR, but not for those with elevated NLR. Pre-treatment NLR is a strong prognostic factor for NPC patients. For patients with locoregionally advanced disease, NLR might also be a useful indicator for selection of treatment strategies.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>21052888</pmid><doi>10.1007/s13277-010-0124-7</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2011-04, Vol.32 (2), p.317-324 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_907181490 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adolescent Adult Aged Biomedical and Life Sciences Biomedicine Cancer Research Cell Count Cellular biology Chemotherapy Child Combined Modality Therapy Drug Therapy Female Head & neck cancer Humans Longitudinal Studies Lymphocytes Lymphocytes - pathology Male Medical prognosis Middle Aged Nasopharyngeal Neoplasms - diagnosis Nasopharyngeal Neoplasms - pathology Nasopharyngeal Neoplasms - therapy Neutrophils - pathology Prognosis Radiation therapy Radiotherapy Research Article Retrospective Studies Secondary Prevention Survival Analysis Young Adult |
| title | Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T09%3A14%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20neutrophil%20to%20lymphocyte%20ratio%20predicts%20poor%20prognosis%20in%20nasopharyngeal%20carcinoma&rft.jtitle=Tumor%20biology&rft.au=An,%20Xin&rft.date=2011-04-01&rft.volume=32&rft.issue=2&rft.spage=317&rft.epage=324&rft.pages=317-324&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-010-0124-7&rft_dat=%3Cproquest_cross%3E907181490%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=852724098&rft_id=info:pmid/21052888&rfr_iscdi=true |